Beta-Adrenergic Inhibition of Pancreatic Secretion in Dogs

Abstract

Terbutaline, a beta-adrenergic agonist, administered subcutaneously inhibits pancreatic exocrine secretion. We studied the effects of intravenous terbutaline and propranolol on cholecystokinin-stimulated pancreatic secretion in conscious dogs. Terbutaline inhibited pancreatic juice volume, bicarbonate concentration, bicarbonate output and protein output, but had no effect on protein concentration. Propranolol blocked this inhibition and had no effect on the response to cholecystokinin. These observations suggest that (1) terbutaline inhibits pancreatic secretion by a beta-adrenergic mechanism and (2) the primary effect of terbutaline on canine exocrine pancreas is inhibition of water and bicarbonate secretion.

Hepatic Denervation Induces Supersensitivity to Terbutaline of the Hepatic Arterial System in Conscious Dogs

“…In addition, interesting actions of intravenous terbutaline have been shown in the pancreas. It significantly inhibits the secretin-stimulated output of pancreatic juice in healthy volunteers [22]. This compound was preliminarily reported by Bergmann et al in 1969 [25].…”

“…adrenoceptors and fewer cardiac side effects in humans than other adrenergic agents [21,22]. We believe that The liver is richly innervated by sympathetic and terbutaline could increase hepatic blood flow without parasympathetic nerves.…”